Page 6,676«..1020..6,6756,6766,6776,678..6,6906,700..»

BIND Biosciences Appoints Andrew J. Hirsch as Chief Financial Officer

Posted: Published on July 17th, 2012

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, today announced that Andrew J. Hirsch has joined the company as its Chief Financial Officer. Mr. Hirsch brings nearly twenty years of financial leadership and strategic management experience. We are very pleased to welcome Andrew to the BIND team, said Scott Minick, President and Chief Executive Officer of BIND Biosciences. Andrew has been an outstanding performer in the biotechnology industry, including major accomplishments with high-growth companies in financing, M&A transactions, strategic planning and investor relations, and his experience will add additional strength to our management team as our growth accelerates. This is an exciting time to be joining BIND as BIND-014, the companys lead Accurin drug candidate continues to show promise as an important medicine for solid tumors as it advances in the clinic and the companys platform for developing highly selective targeted therapeutics is generating a pipeline of important medicines for patients., said Andrew Hirsch. Prior to joining BIND, Mr. Hirsch was Chief Financial Officer at Avila Therapeutics until its acquisition by Celgene Inc. in March 2012. Previously, Mr. Hirsch served in roles of increasing responsibility during … Continue reading

Comments Off on BIND Biosciences Appoints Andrew J. Hirsch as Chief Financial Officer

BioView and ScreenCell Announce Worldwide Commercial Collaboration Agreement for Circulating …

Posted: Published on July 16th, 2012

REHOVOT, Israel and PARIS - BioView Ltd. (TASE: BIOV) and ScreenCell, a privately-held company, today jointly announced the signing of a commercial collaboration agreement for Bioview's Automated Cell Imaging Systems for imaging of CTC's isolated with ScreenCell's Cyto Kit. Dr. Alan Schwebel, President and CEO of BioView, views this agreement as a unique combination of two innovative technologies, one designed by ScreenCell to isolate rare cells of potentially significant prognostic and predictive value in cancer, and another, BioView's scanning platform, which provides automated imaging and analysis solutions for rare cell and circulating tumor cell detection. "BioView's unique automated imaging and analysis solutions for the detection and of rare cells greatly enhance research and clinical laboratory productivity and assay development process. We are proud to be ScreenCell's global partner and look forward to expanding our relationship." Bioview's Imaging Systems are designed to accommodate both the need for CTC enumeration and retrieval of cellular and marker characteristics of captured cells. Utilizing field-proven algorithms developed and perfected in collaboration with leading cancer research centers worldwide, BioView's scanning platform is the ideal solution for both clinical and research laboratories wishing to enhance their productivity and assay development processes. ScreenCell offers innovative, single-use devices to … Continue reading

Posted in Mesenchymal Stem Cells | Comments Off on BioView and ScreenCell Announce Worldwide Commercial Collaboration Agreement for Circulating …

'Strange Sex': Man Battles Erectile Dysfunction By Breastfeeding (VIDEO)

Posted: Published on July 16th, 2012

"The Bachelor" "The Bachelor," ABC Status: Renewed Why: You really think we've seen the last rose handed out? Not in a million years. ABC has already tapped their next "Bachelorette," and we know they'll have their eyes peeled for a hot rejected man from that spinoff to be the next "Bachelor." "The Bachelorette," ABC Status: Likely to be renewed Why: "Bachelor" Brad's also-ran Emily Maynard is getting her turn as the rose giver for the seventh season of "The Bachelorette" this summer. As long as there are people willing to look for love on reality TV, this show will keep on trucking. "Body of Proof," ABC Status: Renewed Why: "Body of Proof" has been falling below its timeslot competitor, CBS's "Unforgettable," but it still draws a decent audience and its fans are very vocal. ABC has decided it deserves a third season. "Castle," ABC Status: Renewed Why: This show's ratings have definitely suffered without "Dancing With the Stars" airing beforehand, but it is a consistent performer. And now that Castle and Beckett's relationship is evolving, a fifth season of "oh yes they will" is a no-brainer. "Charlie's Angels," ABC Status: Canceled Why: Not really a shock for anybody, but "Charlie's … Continue reading

Posted in Erectile Dysfunction | Comments Off on 'Strange Sex': Man Battles Erectile Dysfunction By Breastfeeding (VIDEO)

NeoStem’s Subsidiary, Progenitor Cell Therapy, and SOTIO Enter Into a Phase 3 Manufacturing Services Agreement

Posted: Published on July 16th, 2012

ALLENDALE, N.J. and WILMINGTON, Del., July 16, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) and its subsidiary, Progenitor Cell Therapy, LLC ("PCT"), an internationally recognized Contract Development and Manufacturing Organization (CDMO), and SOTIO, LLC, a Delaware limited liability company that is responsible for organizing the U.S. part of a global pivotal Phase 3 clinical trial of SOTIO, LLC's affiliate, SOTIO a.s. ("SOTIO"), announced today that SOTIO, LLC has retained the services of PCT to manufacture clinical products for SOTIO's U.S. part of a global pivotal Phase 3 clinical trial. SOTIO, LLC is an affiliate of a Czech Republic-based biotechnology company developing new therapies based on activated dendritic cells, focusing on the treatment of cancer and autoimmune diseases. SOTIO, LLC will use the services of PCT to transfer and qualify at PCT's Allendale, New Jersey facility, SOTIO's GMP manufacturing process for the U.S. part of a global pivotal Phase 3 clinical trial for SOTIO's autologous dendritic cell vaccine expected to launch in early 2013, subject to FDA approval. As part of this agreement, PCT will complete a technology transfer of SOTIO's current product manufacturing and analytical procedures into PCT's ongoing CDMO operations. PCT will then implement and perform process qualification … Continue reading

Posted in Cell Therapy | Comments Off on NeoStem’s Subsidiary, Progenitor Cell Therapy, and SOTIO Enter Into a Phase 3 Manufacturing Services Agreement

NeoStem's Subsidiary, Progenitor Cell Therapy, and SOTIO Enter Into a Phase 3 Manufacturing Services Agreement

Posted: Published on July 16th, 2012

ALLENDALE, N.J. and WILMINGTON, Del., July 16, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) and its subsidiary, Progenitor Cell Therapy, LLC ("PCT"), an internationally recognized Contract Development and Manufacturing Organization (CDMO), and SOTIO, LLC, a Delaware limited liability company that is responsible for organizing the U.S. part of a global pivotal Phase 3 clinical trial of SOTIO, LLC's affiliate, SOTIO a.s. ("SOTIO"), announced today that SOTIO, LLC has retained the services of PCT to manufacture clinical products for SOTIO's U.S. part of a global pivotal Phase 3 clinical trial. SOTIO, LLC is an affiliate of a Czech Republic-based biotechnology company developing new therapies based on activated dendritic cells, focusing on the treatment of cancer and autoimmune diseases. SOTIO, LLC will use the services of PCT to transfer and qualify at PCT's Allendale, New Jersey facility, SOTIO's GMP manufacturing process for the U.S. part of a global pivotal Phase 3 clinical trial for SOTIO's autologous dendritic cell vaccine expected to launch in early 2013, subject to FDA approval. As part of this agreement, PCT will complete a technology transfer of SOTIO's current product manufacturing and analytical procedures into PCT's ongoing CDMO operations. PCT will then implement and perform process qualification … Continue reading

Posted in Cell Therapy | Comments Off on NeoStem's Subsidiary, Progenitor Cell Therapy, and SOTIO Enter Into a Phase 3 Manufacturing Services Agreement

Official – drugs a massive problem!

Posted: Published on July 16th, 2012

By Leo Olivero Last week during the budget session the Government described drugs as a massive problem the Police Authority said the issue is of considerable concern the PDP have said of the need to eliminate the alcohol and drugs problem amongst our youth the Courts of have warned of their concern also Organisations and Groups have repeatedly registered their own concerns on drugs Parents and Families particularly those who have had a direct drug issue to contend with have also expressed their strong opinions You would think that just about covers everyone in Gibraltar? Well, you would be wrong! The GSD opposition still in complete drugs denial The GSD now in Opposition as they were when in Government are still in Complete Denial regarding drug abuse in Gibraltar. But this is to be expected, particularly after they did very little during their term in office to tackle this serious and growing social problem. In fact reading Mr, Nettos the shadow spokesman for social services budget address there was no mention relating to the drug problem as such yet I say again, no surprises there for me after the calamitous handling by the GSD of the serious drug problem, something … Continue reading

Posted in Drugs | Comments Off on Official – drugs a massive problem!

Caught in Honduras drugs crossfire

Posted: Published on July 16th, 2012

Please turn on JavaScript. Media requires JavaScript to play. Stephen Sackur joins a navy patrol crew in Honduras trying to stop the smuggling of cocaine to the United States. Honduras is in the grip of a drugs war with US drug enforcement agents helping local forces fight organised gangs, who traffic tons of cocaine destined for the United States, as HARDtalk's Stephen Sackur reports. The deep bullet wound in Hilda Lezama's thigh is a livid pointer to Honduras's unwanted status as a new frontline in America's war on drugs. For all of her 53 years, Hilda Lezama has lived in Ahuas, a settlement of wooden homes built on stilts, close to the fast-flowing Patuca river in the remote Mosquitia region of eastern Honduras. She was shot in a US-led counter-narcotics raid on a riverboat two months ago. Four other local people, including two local women, were killed in the airborne attack which involved US drug enforcement agents and Honduran troops. "We were returning from a trip down-river with the fishermen," Hilda recalled. "We travelled at night to avoid the heat. We heard the helicopters above us, but we couldn't see them. "They could have let us dock and then searched … Continue reading

Posted in Drugs | Comments Off on Caught in Honduras drugs crossfire

Research and Markets: 2012 Outsourcing Guide for the Drugs & Biotechnology Industry

Posted: Published on July 16th, 2012

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/mj7whg/2012_outsourcing_g) has announced the addition of the "2012 Outsourcing Guide for the Drugs & Biotechnology Industry" report to their offering. The Drugs & Biotechnology industry profile includes four components: 1) Market Situation 2) Outsourcing Trends 3) ISG Observations 4) Several pages of outsourcing data. The data, graphics and analysis provide insight into outsourcing activity within the Drugs & Biotechnology vertical and subvertical levels, including 'Biotechs' and 'Pharmaceuticals'. This report from the ISG Momentum Market Trends & Insights series can help service providers develop an effective go-to-market strategy characterized by better targeting of opportunities and higher win and retention rates. The charts and graphics answer questions about market size and direction, as well as buying and spending patterns, allowing service providers to enhance account planning activity. All of the data in this report is based on the proprietary ISG Pervasiveness Research and ISG Databases, which are used to create the ISG Index and ISG Index Insider, among other publications. ISG is the founder of the sourcing advisory industry and the leading independent sourcing data and advisory firm in the world. The company's world-class global advisory staff works hand- in-hand with clients as they develop their outsourcing … Continue reading

Posted in Drugs | Comments Off on Research and Markets: 2012 Outsourcing Guide for the Drugs & Biotechnology Industry

Sex, Drugs, and Paper Towels

Posted: Published on July 16th, 2012

By Liz Hoffmann - July 16, 2012 | Tickers: CVS, ESRX, WAG | 0 Comments Liz is a member of The Motley Fool Blog Network -- entries represent the personal opinions of our bloggers and are not formally edited. What do sex, drugs, and paper towels have in common? They all have devotees who shop at CVS Caremark (NYSE: CVS). Whether it's young men and women for birth control, the sick and elderly for prescription drugs, or growing families for baby supplies and paper towels, you'll find them all at a CVS. And that's just the tip of the iceberg when it comes to the number of products distributed and demographic groups served. Now for some specifics: CVS has been on a respectable growth trajectory for the past 5 years, with revenues for that period increasing 19.57% and EPS growing at 10.11%. Dividends are paid quarterly and in 2012 have increased 30% versus the year ago perioddriving a 1.35% annualized dividend yield. And for the past 52 weeks, the stock has performed admirably logging a robust 27.44% increase in price. On Thursday, July 5th CVS reached its all-time high of $48.32 per share. It should be no surprise then that … Continue reading

Posted in Drugs | Comments Off on Sex, Drugs, and Paper Towels

Research and Markets: Medicinal Chemistry of Anticancer Drugs

Posted: Published on July 16th, 2012

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/pd8hns/medicinal_chemistr) has announced the addition of Elsevier Science and Technology's new report "Medicinal Chemistry of Anticancer Drugs" to their offering. Antitumour chemotherapy is nowadays a very active field of research, and a huge amount of information on the topic is generated every year. Although many books are available that deal with clinical aspects of cancer chemotherapy, this book addresses the need for an updated treatment from the point of view of medicinal chemistry and drug design. Cytotoxic chemotherapy is gradually being supplemented by a new generation of drugs that recognize specific targets on the surface or inside cancer cells. These therapies are in their infancy, but they hold promise of more effective therapies with fewer side effects. Resistance to antitumour drugs is another important but normally neglected field. The focus of Medicinal Chemistry of Anticancer Drugs is on the mechanism of action of antitumour drugs from the molecular point of view and on the relationship between chemical structure and chemical and biochemical reactivity of antitumour agents, aiming at the rationalization of the action of this type of drugs, which would allow the design of new active structures. - Presents information in a clear and concise … Continue reading

Posted in Drugs | Comments Off on Research and Markets: Medicinal Chemistry of Anticancer Drugs

Page 6,676«..1020..6,6756,6766,6776,678..6,6906,700..»